Gamma-aminobutyric acid type A receptor and alpha-2 adrenergic receptor (GABA-AR and Alpha-2AR)

The Gamma-aminobutyric acid type A (GABA-A) receptor and the alpha-2 adrenergic receptor are distinct molecular entities that serve as primary inhibitory regulators within the central nervous system. The GABA-A receptor is a pentameric ligand-gated ion channel that facilitates the influx of chloride ions, leading to neuronal hyperpolarization and rapid inhibition of synaptic activity [1, 2]. In contrast, the alpha-2 adrenergic receptor is a G protein-coupled receptor that inhibits adenylyl cyclase and reduces the presynaptic release of norepinephrine, thereby modulating sympathetic tone and nociception [3, 4]. Although they operate through different signaling pathways, these receptors are frequently co-targeted in clinical settings, particularly in anesthesia and intensive care, to achieve synergistic sedation and analgesia [5]. Drugs such as benzodiazepines and propofol act on GABA-A receptors to provide anxiolysis and hypnosis, while alpha-2 agonists like dexmedetomidine offer sedative properties with a unique lack of respiratory depression [3, 6]. The combined pharmacological modulation of these systems is a cornerstone of modern multimodal therapy for managing pain, agitation, and neurological disorders [5].

Other names

GABA-A receptorAlpha-2 adrenoceptorGABAA-RADRA2Alpha-2 adrenergic receptor

GABA-A receptors function as ligand-gated chloride channels that mediate fast inhibitory neurotransmission in the central nervous system [1]. Alpha-2 adrenergic receptors are Gi/o-coupled receptors that inhibit adenylyl cyclase, decrease cAMP levels, and reduce presynaptic norepinephrine release [3].